Related Experiment Video
Updated: Jul 24, 2026
Assessment and Evaluation of the High Risk Neonate: The NICU Network Neurobehavioral Scale
Published on: August 25, 2014
Practical Application of Nirsevimab Recommendations for Infants and Toddlers
Insights
Nirsevimab offers 90% protection against severe respiratory syncytial virus (RSV) hospitalization in infants. This long-acting antibody provides crucial prevention for vulnerable populations, addressing caregiver hesitancy and health equity concerns.
Area of Science:
- Pediatrics
- Infectious Diseases
- Immunology
Background:
- Respiratory syncytial virus (RSV) is a primary cause of infant hospitalization due to bronchiolitis and pneumonia.
- Severe RSV disease disproportionately affects infants and young children.
- Nirsevimab is a novel long-acting monoclonal antibody for RSV prevention.
Purpose of the Study:
- To review the mechanism of action, safety, and efficacy of nirsevimab.
- To outline prescribing recommendations for nirsevimab in infants and high-risk toddlers.
- To address challenges in nirsevimab implementation, including caregiver hesitancy and health equity.
Main Methods:
- Review of recent clinical trial data on nirsevimab efficacy.
- Analysis of nirsevimab's pharmacokinetic and pharmacodynamic properties.
- Consideration of public health guidelines and special prescribing circumstances.
Main Results:
- Nirsevimab demonstrated 90% protection against severe RSV disease hospitalization in infants during their first RSV season.
- The monoclonal antibody is recommended for all infants under 8 months and certain high-risk toddlers.
- Implementation requires addressing caregiver concerns and ensuring equitable access.
Conclusions:
- Nirsevimab is a highly effective tool for preventing severe RSV disease in infants.
- Understanding nirsevimab's profile is crucial for healthcare providers to optimize its use.
- Special populations and potential drug shortages necessitate careful, equitable prescribing strategies.
Abstract:
Respiratory syncytial virus (RSV) is a common respiratory tract infection that causes bronchiolitis and pneumonia in infants and children. It is the leading cause of hospitalization of infants in the United States. Nirsevimab is a long-acting monoclonal antibody recommended for the prevention of severe disease in all infants under 8 months of age and certain high-risk toddlers. Recent data demonstrate a 90% protection against hospitalization from severe RSV disease for infants who received nirsevimab in their first RSV season. Providers should understand the mechanism of action, safety, efficacy, and prescribing recommendations for nirsevimab, especially when confronted with caregivers who are hesitant about medications and vaccines. Special circumstances may require nuanced prescribing of nirsevimab to safely provide optimal protection. In these circumstances, and during drug shortages, a lens of health equity should be used to protect the highest risk populations.
Related Concept Videos
01:29Drug Dosing: Infants and Children
01:29Respiratory Syncytial Virus Disease